Active TED patients showed higher thyrotropin receptor antibody levels and increased DCP vessel density.
The FDA granted breakthrough therapy designation to privosegtor, a novel peptoid small molecule for the treatment of optic ...
The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
Oculis Holding (OCS) added ~11% on Tuesday after the Swiss drug developer announced the breakthrough therapy designation for ...
Jennifer E. Thorne, MD, PhD, is the Cross Family Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University School of Medicine in Baltimore, Maryland.
High axial myopia is linked to increased prevalence of nonglaucomatous, glaucoma-like, and glaucomatous optic neuropathies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback